PTX Stock Overview
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Prescient Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.05 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.045 |
| Beta | 1.1 |
| 1 Month Change | -5.66% |
| 3 Month Change | -9.09% |
| 1 Year Change | -47.37% |
| 3 Year Change | -42.53% |
| 5 Year Change | 16.28% |
| Change since IPO | -33.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PTX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -12.3% | -1.2% | -1.5% |
| 1Y | -47.4% | -7.4% | 5.7% |
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned -7.4% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
| PTX volatility | |
|---|---|
| PTX Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PTX's share price has been volatile over the past 3 months.
Volatility Over Time: PTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Steven Yatomi-Clarke | ptxtherapeutics.com |
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR.
Prescient Therapeutics Limited Fundamentals Summary
| PTX fundamental statistics | |
|---|---|
| Market cap | AU$40.27m |
| Earnings (TTM) | -AU$7.74m |
| Revenue (TTM) | AU$3.11m |
12.4x
P/S Ratio-5.0x
P/E RatioIs PTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTX income statement (TTM) | |
|---|---|
| Revenue | AU$3.11m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.11m |
| Other Expenses | AU$10.86m |
| Earnings | -AU$7.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0096 |
| Gross Margin | 100.00% |
| Net Profit Margin | -248.74% |
| Debt/Equity Ratio | 0% |
How did PTX perform over the long term?
See historical performance and comparison